leisure time -WSS

leisure time

author：explore 2025-10-02 04:35:31 - browse：729

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Advances in CAR

leisure time

focus

WSS

How to fix cancer clinical trials' diversity problem

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Ethical issues complicate the benefits of medical crowdfunding

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Advances in CAR

Wegovy trial has doctors encouraged over new possibilities

focus

leisure time

explore

Medical records are filled with copy

FDA panel issues narrow recommendation for Covid vaccine booster doses

United colonoscopy coverage change 'may cost lives,' doctors say

Illumina names Agilent executive as new CEO

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Humana sues Biden admin over Medicare Advantage audit rule

Jerome Adams on the need for new antivirals for Covid

Wegovy trial has doctors encouraged over new possibilities

Novavax promises a turnaround & Lilly roils the obesity market

House transparency, PBM reform bill gains bipartisan support

hotspot

NIH nominee Bertagnolli will get October confirmation hearing

Snackable artificial intelligence, expert AI, and the pharma industry

The best solution to the drug shortages problem

The (many) problems with a new study criticizing cancer screening

Trump surgeon general acknowledges mistakes during Covid

How generative AI is inspiring dreams of a health data revolution

leisure time

focus

explore

Wikipedia